修订后的ALS功能评级尺度的自然历史及其与生存的关联:精密ALS现有研究
Ruben P A van Eijk1,2, Daphne N Weemering1, Sarah Opie-Martin3
1Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.
概括
修订后的ALS功能评级尺度 (ALSFRS-R) 显示,肌缩侧面硬化症 (ALS) 患者的病情正在逐渐下降. 当前功能和变化速度都会影响生存,这对药物开发至关重要.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 生物统计学 生物统计学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 修订后的ALS功能评级尺度 (ALSFRS-R) 是临床试验中一个关键的结果指标.
- 了解ALSFRS-R进展的自然史对于解释治疗效应至关重要.
研究的目的:
- 描述ALSFRS-R.的24个月自然历史.
- 评估ALSFRS-R轨迹与患者存活率之间的关联.
- 为了提供一个更精确的估计人口下降率在ALS.
主要方法:
- 利用了来自欧洲七个基于人口的队列的纵向ALSFRS-R和生存数据.
- 采用联合建模框架来计算死亡率.
- 评估了ALSFRS-R轨迹的非线性模型,并测试了队列差异.
主要成果:
- 包括7030名患者,在10,285人年内测量了31,746个ALSFRS-R测量结果.
- 在所有队列中表现出非线性,减速的ALSFRS-R进展 (p < 0.001).
- 发现当前的ALSFRS-R得分和变化率都与生存显著相关 (p < 0.001).
结论:
- 功能性下降在ALS遵循一个减速的轨迹.
- 当前的功能状态和变化速度直接影响ALS患者的生存率.
- 这些发现有助于区分治疗效应与自然疾病进展在ALS药物开发中.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
83
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
83
Assumptions of Survival Analysis
56
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
56
Actuarial Approach
39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39
The Mantel-Cox Log-Rank Test
225
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
225
Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
Kaplan-Meier Approach
52
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
52


